Compare Amgen, Inc. (AMGN) vs Krispy Kreme Inc (DNUT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Krispy Kreme Inc — how do they compare? Amgen, Inc. trades at $361.84 (market cap $196.12B), while Krispy Kreme Inc trades at $3.48 (market cap $593.06M). The key difference: Amgen, Inc. is far larger — about 330.7× Krispy Kreme Inc's market cap, and Krispy Kreme Inc pays the higher dividend (3.47%). Which is the better fit depends on your goals.
| AMGN | DNUT | |
|---|---|---|
Market Cap | $196.12B | $593.06M |
Sector | Health | Consumer Staples |
52-Week High | $388.16 | $4.70 |
52-Week Low | $271.18 | $2.92 |
Enterprise Value | $241.41B | $1.79B |
Dividend Yield | 2.77% | 3.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Krispy Kreme (DNUT) trades at $3.44, up 0.58% today, amid bearish technical signals and mixed fundamentals. The stock shows negative profitability with a -33.36% net margin and -58.92% ROE, though revenue remains stable near $1.5B. Recent Q1 2026 earnings missed expectations, but Q3 and Q4 2025 beat forecasts. Analyst sentiment is cautiously optimistic with 50% buy ratings, while technical indicators point to resistance near $4.
Outlook hinges on execution of capital-light expansion and cost controls. Risks include persistent losses and high debt, but potential upside exists if turnaround initiatives boost margins. Investors should weigh analyst optimism against weak cash flow trends and competitive pressures in the consumer staples sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →
